CAR-T Cell Therapy Timeline: From Collection to Recovery

The CAR-T cell therapy timeline runs to at least 40 to 45 days, and Dr. Akash Khandelwal, Consultant Hemato-Oncology & BMT, Fortis Hospital, Shalimar Bagh, New Delhi, India, advises patients to allow two months. The course has five stages: T-cell collection, manufacture with a 19-day vein-to-vein time, conditioning chemotherapy, infusion, and recovery with three months of close monitoring.

CAR-T cell therapy is often described as a single infusion. In practice each of those stages has its own failure points, and the infusion itself is one of the shortest. This article follows the two-month pathway stage by stage, including the complications that define the recovery period. How the therapy works and where it is heading are covered in CAR-T cell therapy: a complete guide.

Stage 1: How T cells are collected for CAR-T (apheresis)

T cells for CAR-T are collected from the patient's own blood by apheresis, with no preparatory drugs. Because every CAR-T product currently available is autologous, the raw material is the patient's own blood. Apheresis uses the same type of machine that collects stem cells from a donor or single-donor platelets from a blood donor: the patient's blood is connected to the machine and the T cells are filtered out.

Two features distinguish this collection from a stem cell harvest:

• No mobilisation is needed. No drugs are given beforehand. As Dr. Khandelwal puts it, all that is required is a vein.
• The yield decides everything that follows. If the appropriate number of T cells is collected, manufacturing can begin. If it is not, the treatment cannot go ahead.

Dr. Khandelwal calls collection the most crucial step of the entire process and the rate-limiting step for CAR-T. Inadequate collection happens in roughly 5 to 10% of cases. When it does, there is little to be done in the short term: the team waits and makes a second collection attempt after about six months.

This is also where a patient's general condition matters most. Asked in the masterclass Live Discussion whether nutrition plays a role in CAR-T, Dr. Khandelwal's answer was that poor nutrition can affect whether the desired T cells are obtained, and that this is the point at which it counts. Beyond collection, he does not see nutrition as a deciding factor, because the chemotherapy used in CAR-T is not heavy. Even a frail patient, in his view, can undergo the therapy. Candidates are still assessed for performance status and organ function before CAR-T. Cachexia, in his experience, plays a larger role in bone marrow transplantation than in CAR-T.

Stage 2: How the CAR-T product is manufactured

The collected T cells are sent to a dedicated laboratory, where they are reprogrammed and the chimeric antigen receptor is attached. The modified cells are then expanded, one CAR-T cell becoming many, until the dose reaches the required level.

Dr. Khandelwal puts the target expansion at approximately 5 to 10 million CAR-T cells per kilogram of body weight. The cut-off is 5 million cells per kilogram: below that, the product is not adequate. Each batch is quality-controlled before release.

Manufacturing is the second point at which a course can fail. Even after a successful collection, Dr. Khandelwal puts the chance that the CAR-T product cannot be manufactured properly at about 2%.

A third point of failure comes after infusion. The CAR-T cells are meant to multiply inside the patient's body once they find their target, and this in vivo expansion is linked to response: when the infused cells fail to expand adequately, the chance of a durable remission falls.

What is the CAR-T vein-to-vein time?

The interval from T-cell collection to the moment the finished product is back with the treating team for infusion is called the vein-to-vein time. For the products Dr. Khandelwal uses, it is 19 days. Those 19 days cover reprogramming, expansion and quality control, and they are the period in which the patient is, in effect, waiting while the disease may progress.

Stage 3: Can CAR-T infusion be postponed?

CAR-T infusion can be postponed for up to three months from the time of processing, because the finished product is cryopreserved (frozen for storage) and its quality holds. That buffer answers a real clinical risk created by the 19-day gap. A collection may go smoothly and the product may be manufactured without a problem, yet by the time it returns the patient's disease may have worsened, or the patient may have become unfit, for example because of an infection. Dr. Khandelwal values this flexibility: it allows the team to take the product on the date that suits the patient's condition rather than the laboratory's schedule, and to stabilise the patient first if needed.

Stage 4: Lymphodepleting chemotherapy and CAR-T infusion

Before the CAR-T cells are infused, the patient receives three days of chemotherapy followed by two days of rest. In the conventional schedule, the chemotherapy is given on days -5, -4 and -3, days -2 and -1 are rest days, and the CAR-T cells are infused on day 0.

The purpose of this chemotherapy is specific. It is lymphodepleting: it reduces the patient's existing lymphocytes to make space in the body for the incoming CAR-T cells. The regimen consists of cyclophosphamide and fludarabine. Dr. Khandelwal notes that the doses are not high. The chemotherapy can cause cytopenias (low blood counts), including neutropenia, but these are manageable, which is why a patient's fitness is less of a barrier to CAR-T than to a transplant.

Patients are admitted for this phase. The roughly five days of conditioning and rest before infusion are spent in hospital.

Stage 5: CAR-T side effects and recovery

The main side effects after CAR-T are fever and infections, low blood counts, cytokine release syndrome, neurotoxicity (ICANS), HLH and low B cells. Dr. Khandelwal is clear that a successful infusion is not the end of treatment: between the chemotherapy and the CAR-T cells themselves, this recognisable set of complications follows:

• Fever and infections.
• Low blood counts: thrombocytopenia (low platelets) and neutropenia (low white cell count).
• Cytokine release syndrome (CRS), a characteristic complication of CAR-T and other immune effector cell therapies.
• ICANS (immune effector cell-associated neurotoxicity syndrome), which can affect the brain. Dr. Khandelwal has not seen it often, but it is part of the monitoring.
• HLH (haemophagocytic lymphohistiocytosis), a less common but serious hyperinflammatory complication.
• Low B cells and hypogammaglobulinaemia (low antibody levels), which leave patients prone to infections later on.

The last of these matters for long-term follow-up, because the infections it causes can appear well after the infusion. Dr. Khandelwal describes this as a unique category of post-CAR-T infections and complications that demands care.

Is CAR-T safe? How the risk varies between patients

In Dr. Khandelwal's own practice, the side effects of CAR-T have been manageable, and he has not seen a death from CAR-T-associated side effects. That experience should not be read as a guarantee. CAR-T-related side effects vary from patient to patient, whereas the conditioning chemotherapy produces fairly predictable effects. When the disease is well controlled at the time of infusion, the team does not expect many complications, but even with the best disease control a patient can develop CRS or another of the unique complications. Severe cytokine release syndrome and ICANS can be life-threatening and are occasionally fatal, which is why both are graded and treated early, typically with tocilizumab for cytokine release syndrome and corticosteroids for neurotoxicity, by teams experienced in CAR-T care.

How long do patients stay in hospital after CAR-T?

Patients spend the first 15 to 20 days after infusion in hospital, and close monitoring continues for three months. Dr. Khandelwal's protocol is built around when each risk peaks:

• The first 15 to 20 days after infusion are spent in hospital. This covers the window for the initial and most problematic complications: cytokine release syndrome, fever, low platelets, low white cell counts and ICANS.
• Close monitoring continues for three months after infusion, to detect complications early and mitigate them.

The full CAR-T cell therapy timeline: why two months is the minimum

The complete CAR-T process takes at least 40 to 45 days, and Dr. Khandelwal advises patients to allow two months. The full pathway combines two blocks of time:

1. About 19 days of vein-to-vein time while the product is manufactured.
2. About 20 to 25 days of inpatient care in isolation on a bone marrow transplant ward: roughly five days before infusion for conditioning chemotherapy and rest, and 15 to 20 days afterwards to manage early side effects.

Together these give the 40 to 45 days. Dr. Khandelwal treats that as the bare minimum. Any delay, a second collection attempt, a postponed infusion while the patient recovers from an infection, or a slower recovery, extends it further.

For a referring doctor, the timeline has three practical implications. The patient needs to be well enough to give an adequate T-cell collection at the outset, since a failed collection can cost six months. The patient and family need to plan for around two months away from home, much of it in an isolation ward. And follow-up does not end at discharge: the three-month monitoring window, and the later risk of infection from low B cells, need to be built into the plan for the patient's return.

Who qualifies for this pathway, and what results to expect from it, are covered in who is eligible for CAR-T cell therapy, with outcomes and access.